Clinical trials
Acute Hospitalization clinical trials
Below are recruiting acute hospitalization clinical trials, each written for real people, not researchers. We’re tracking 984 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06045156Recruiting
Tirofiban after clot-busting for stroke
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
Changchun, JilinAges 18 years+ - NCT06802718RecruitingPhase 3
Interferon-alpha after Chemo for Favorable-Risk AML
This study tests if a medicine called interferon-alpha can help keep leukemia from coming back after initial treatment. It is for people with a favorable-risk type of AML who still have tiny traces of leukemia-related genetic material after finishing their first round of chemo.
Beijing, Beijing MunicipalityAges 18–70 - NCT06955143Recruiting
Blood study for acute coronary syndrome patients
This study examines blood samples from people with different types of coronary artery disease to understand the condition better. It may help doctors learn how to treat heart problems in the future.
Lishui, ZhejiangAges 18 years+ - NCT07259252Recruiting
Flu vaccine study for heart attack or unstable angina patients
This study tests whether getting a flu vaccine helps people who recently had a heart attack or unstable angina (acute coronary syndrome). It looks at whether vaccination can reduce future heart problems.
Wuhan, HubeiAges 18–80 - NCT07563179RecruitingPhase 2
Bugitinib with Venetoclax and Cytarabine for Relapsed AML
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
Shenzhen, GuangdongAges 18–70 - NCT06120218Recruiting
Stenting for blocked neck and brain artery in severe stroke
This trial tests a treatment for people having a severe stroke when a large artery in the neck and a brain artery are both blocked. The treatment involves opening the neck artery with a stent (a small tube) and then clearing the brain clot, all within 24 hours of symptom onset.
Can ThoAges 19–100 - NCT06613074Recruiting
Smartphone app for stroke triage without ambulance
This trial is testing a smartphone app that helps guide patients with a recent stroke to the right place for care, if they did not come by ambulance. It is for people who have already received clot-busting treatment.
Shaoxing, ZhejingAges 18 years+ - NCT05902416Recruiting
Testing haplo transplant for older adults with leukemia or MDS
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Beijing, Beijing MunicipalityAges 55–70 - NCT07450846Recruiting
Heart-lung interaction in severe breathing problems
This study looks at how the heart and lungs interact in patients with acute respiratory distress syndrome (a severe lung condition) who are on a breathing machine. Researchers will use ultrasound to check heart function at different times during treatment.
Le Kremlin-BicêtreAges 18 years+ - NCT05506332RecruitingPhase 1
Venetoclax plus leukemia drugs for AML after treatment failure
This Phase 1 trial studies whether a combination of venetoclax (ABT-199) and “purine analogues” can help adults with AML that has come back or didn’t respond to earlier treatment. It’s designed to test safety and early effectiveness in people who haven’t previously developed resistance to venetoclax.
Edegem, AntwerpAges 18 years+ - NCT06472128Recruiting
New digital app for adults with acute myeloid leukemia
This study tests a digital application to help patients with acute myeloid leukemia (AML) during their hospital stay. It may assist with tracking symptoms, education, or communication with care teams.
Boston, MassachusettsAges 18–120 - NCT07369999RecruitingPhase 3
Butylphthalide plus tenecteplase for mild disabling stroke
This trial tests whether adding butylphthalide (a drug that improves blood flow) to the standard clot-busting medicine tenecteplase can help people with mild but disabling strokes recover better. If you have had a mild stroke within the last 4.5 hours and are 18–80, this study might be an option for you.
Changsha, HunanAges 18–80 - NCT07130409Recruiting
Heart imaging after emergency angioplasty for first heart attack
This study uses advanced heart scans (MRI) before and after a common artery-opening procedure to see how the heart heals. It only includes people having their first heart attack who get emergency treatment with a stent.
Qingdao, ShandongAges 18–80 - NCT04545242RecruitingPhase 4
Dexamethasone for severe lung failure from infections on ventilators
This trial studies whether dexamethasone (a steroid medicine) improves outcomes in adults who have sudden, severe breathing failure caused by an infection while they are on a breathing machine. It may help reduce inflammation in the lungs during critical illness.
Terrassa, BarcelonaAges 18 years+ - NCT06863974Recruiting
Finding markers of relapsing nerve inflammation in children
This study looks at children who have had a first attack of nerve inflammation (like ADEM, vision loss, or spinal cord issues) to find markers in the blood that might show if it will come back. It tests blood and cells to better understand the immune response.
AngersAges 18 years+ - NCT07517510Enrolling by invitationPhase 2
HVA treatment for newly diagnosed mixed-phenotype acute leukemia
This study tests a drug called HVA to treat mixed-phenotype acute leukemia (MPAL), a rare blood cancer that has features of both lymphoblastic and myeloid leukemias. You may qualify if you've just been diagnosed and haven't started strong anti-cancer treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT05325099RecruitingPhase 1/Phase 2
Azacitidine to help prevent kidney injury after heart surgery
This early-phase study tests whether azacitidine (a medication that changes how cells read genes) can lower the risk of acute kidney injury after cardiac surgery, especially in people already at risk along the chronic kidney disease (CKD) pathway. It aims to protect kidney function during the vulnerable period after surgery.
TaipeiAges 20 years+ - NCT06658197RecruitingPhase 3
Comparing a new clot-busting drug for severe stroke
This study tests a medication called tenecteplase, given before a procedure to remove a large blood clot in the brain. It may help people who have had a severe stroke within the last 4.5 hours.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06949059RecruitingPhase 1/Phase 2
Hydromorphone for acute chest pain relief
This trial tests a quick-acting pain medicine (hydromorphone) given through a vein to treat severe chest pain. It may be an option for people experiencing acute pain who haven't been helped by other medicines.
Nanjing, JiangsuAges 18–64 - NCT06006819Recruiting
Acute heart failure with chronic kidney disease study
This trial studies how certain markers in the blood can predict outcomes in people with acute heart failure who also have chronic kidney disease. If you qualify, researchers will follow your health during this hospital stay.
Taipei, Baitou DistrictAges 20–90 - NCT07152041RecruitingPhase 3
Pediatric Ph+ B-ALL treatment trial
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT05561088Recruiting
Head acupuncture after stroke clot removal
This trial studies whether doing head acupuncture after a procedure to remove a stroke-causing blood clot can improve recovery and safety. You may be considered if you had endovascular clot removal within 24 hours and meet specific brain-scan and stroke-severity measures.
Xi'an, ShaanxiAges 18–100 - NCT06194968Recruiting
Stroke treatment with urokinase in real-world settings
This study looks at how well the clot-busting drug urokinase works for treating acute ischemic stroke in everyday medical practice. It may help if you have had a stroke and are eligible for clot-dissolving medication.
Lanzhou, GansuAges 18 years+ - NCT06650137Recruiting
Using Diaphragm Ultrasound to Find the Cause of Breathing Trouble
This study tests if ultrasound of your diaphragm (the muscle that helps you breathe) can help doctors find the cause of sudden breathing trouble. It may help patients who come to the emergency room with fast or difficult breathing and low oxygen levels.
Nîmes, GardAges 18 years+
Hear when a new Acute Hospitalization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute hospitalization?
- Yes. Clin2 currently lists 984 recruiting acute hospitalization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute hospitalization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute hospitalization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.